Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment

Dow Jones12-18 05:21

By Elias Schisgall

Insmed is discontinuing its development of brensocatib after a Phase 2b study found that the chronic rhinosinusitis treatment failed to meet its primary or secondary efficacy endpoints.

The Bridgewater, N.J.-based pharmaceutical company also said Wednesday that it was acquiring INS1148, an investigational monoclonal antibody that could be used to treat respiratory, immunological, and inflammatory conditions.

Insmed said it plans to launch Phase 2 development programs to study INS1148 in treating interstitial lung disease and moderate-to-severe asthma.

The antibody treatment was first developed by Opsidio, a clinical-stage private pharmaceutical company.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. "Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment," at 4:21 p.m. ET, incorrectly said the company was ending full development of the drug.

(END) Dow Jones Newswires

December 17, 2025 19:12 ET (00:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592748943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592748943","market":"other","top_or_hot":-1,"title":"Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INSM\">Insmed</a> is discontinuing its development of brensocatib after a Phase 2b study found that the chronic rhinosinusitis treatment failed to meet its primary or secondary efficacy endpoints. \n</p>\n<p>\n  The Bridgewater, N.J.-based pharmaceutical company also said Wednesday that it was acquiring INS1148, an investigational monoclonal antibody that could be used to treat respiratory, immunological, and inflammatory conditions. \n</p>\n<p>\n  Insmed said it plans to launch Phase 2 development programs to study INS1148 in treating interstitial lung disease and moderate-to-severe asthma. \n</p>\n<p>\n  The antibody treatment was first developed by Opsidio, a clinical-stage private pharmaceutical company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. \"Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment,\" at 4:21 p.m. ET, incorrectly said the company was ending full development of the drug. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 19:12 ET (00:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-18 05:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INSM\">Insmed</a> is discontinuing its development of brensocatib after a Phase 2b study found that the chronic rhinosinusitis treatment failed to meet its primary or secondary efficacy endpoints. \n</p>\n<p>\n  The Bridgewater, N.J.-based pharmaceutical company also said Wednesday that it was acquiring INS1148, an investigational monoclonal antibody that could be used to treat respiratory, immunological, and inflammatory conditions. \n</p>\n<p>\n  Insmed said it plans to launch Phase 2 development programs to study INS1148 in treating interstitial lung disease and moderate-to-severe asthma. \n</p>\n<p>\n  The antibody treatment was first developed by Opsidio, a clinical-stage private pharmaceutical company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 16:21 ET (21:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592748943","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592748943","pubTimestamp":1766006460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Insmed is discontinuing its development of brensocatib after a Phase 2b study found that the chronic rhinosinusitis treatment failed to meet its primary or secondary efficacy endpoints.The Bridgewater, N.J.-based pharmaceutical company also said Wednesday that it was acquiring INS1148, an investigational monoclonal antibody that could be used to treat respiratory, immunological, and inflammatory conditions.Insmed said it plans to launch Phase 2 development programs to study INS1148 in treating interstitial lung disease and moderate-to-severe asthma.The antibody treatment was first developed by Opsidio, a clinical-stage private pharmaceutical company.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"Insmed因研究失败而结束鼻窦药物开发，获得抗体治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\nInsmed is discontinuing its development of brensocatib after a Phase 2b study found that the chronic rhinosinusitis treatment failed to meet its primary or secondary efficacy endpoints. \n\n\n  The Bridgewater, N.J.-based pharmaceutical company also said Wednesday that it was acquiring INS1148, an investigational monoclonal antibody that could be used to treat respiratory, immunological, and inflammatory conditions. \n\n\n  Insmed said it plans to launch Phase 2 development programs to study INS1148 in treating interstitial lung disease and moderate-to-severe asthma. \n\n\n  The antibody treatment was first developed by Opsidio, a clinical-stage private pharmaceutical company. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n\n \n\n\n  Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. \"Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment,\" at 4:21 p.m. ET, incorrectly said the company was ending full development of the drug. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 19:12 ET (00:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592748943","isCrawlerRequest":true}